Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD

Inclusion Criteria: * Signed informed consent. * Symptomatic chronic LBP due to moderate IDD (modified Pfirrmann score 3-4, Griffith score 3-7) at max.3 levels of the lumbar spine unresponsive to conservative treatment, physical and medical for at least 6 months. Physical treatment includes physiotherapy. Medical treatments includes nonsteroidal anti-inflammatory drugs (NSAID), paracetamol, opioids and myorelaxant. * Annulus fibrosus intact, demonstrated by MRI. * Pain baseline \> 40 mm on VAS (0- 100). * NSAID washout of at least 2 days before screening. * Painkillers washout of at least 24 hours before screening. * For females of childbearing potential, a negative pregnancy test must be documented at Screening. * Men and women should use effective contraception during treatment and for at least 24 months after BM-MSC discontinuation. As a precautionary measure, breast-feeding should be discontinued during treatment with BM-MSC and should not be restarted after discontinuation of BM-MSC. Exclusion Criteria: * Congenital or acquired diseases leading to spine deformations that may upset cell application (scoliosis, isthmus lesion, sacralization and hemisacralization, degenerative spondylolisthesis). * Spinal segmental instability assessed by dynamic X-Ray. * Symptomatic facet joints syndrome on MRI (facet joints hyperintensity and hypertrophy evaluated at coronal T2 weighted MRI). * Prior to the screening visit, has received: * Oral corticosteroid therapy within the previous 3 months, OR * Intramuscular, intravenous or epidural corticosteroid therapy within the previous 3 months * Presence of a 4th level with symptomatic IDD (modified Pfirrmann score 3-4, Griffith score 3-7) in the lumbar spine. * Spinal canal stenosis (Schizas score \> B). * History of spinal infection. * Lumbar disc herniation and sciatica. * Endplate abnormality such as Schmorl's Nodes. * Previous discal puncture or previous spine surgery. * IDD with Modic II and III changes on MRI images. * Patients not eligible to the intravertebral disc surgery. * Patients who have the risk to undergo a surgery in the next 6 months. * Patients with local infusion device/devices for corticosteroids. * Obesity with body mass index (BMI in Kg/size in m\^2) greater than 35 (obesity grade II). * Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study. * Abnormal blood tests: hepatic (alanine amino transferase \[ALT\] and/or as…